title: Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.
authors.affiliation: Department of Hematology, Hospital de Mataró, Mataró, Barcelona, Spain. jahernandez@csm.scs.es
authors.forename: José-Angel
authors.initials: JA
authors.lastname: Hernández
authors.forename: Raúl
authors.initials: R
authors.lastname: Diloy
authors.forename: David
authors.initials: D
authors.lastname: Salat
authors.forename: Neus
authors.initials: N
authors.lastname: del Río
authors.forename: Xavier
authors.initials: X
authors.lastname: Martínez
authors.forename: Josep-María
authors.initials: JM
authors.lastname: Castellví
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D009154:Mutation; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine; D000069283:Rituximab